Completing data — refresh the page later to see the latest
132296-11-8CCCCCCCC(C)(C)c1ccc([C@H]2CCC[C@@H](O)C2)c(O)c1HNMJDLVMIUDJNH-PKOBYXMFSA-N132296-11-8、70434-92-3DTXSID30875420Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Temporary listing of substances subject to emergency scheduling. Any material, compound, mixture or preparation which contains any quantity of the following substances. 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers (DEA Code Number: 7298) are included on this list.
SRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
/SIGNS AND SYMPTOMS/ Although gastrointestinal effects, such as nausea, vomiting, and retching, are the most common after consumption of /synthetic cannabinoids/, cardiovascular effects, such as extremely elevated heart rate and blood pressure, chest pain, and cardiac ischemia are among the most dangerous consequences. Occasional inappropriate laughter, injected conjunctiva, xerostomia, and nystagmus have been described as well. /Synthetic cannabinoids/ also induces metabolic effects, such as hypokalemia, hyperglycemia, and acidosis, and autonomic effects, such as fever and mydriasis. /Synthetic cannabinoids/
/SIGNS AND SYMPTOMS/ In general, the desired effects of /synthetic cannabinoids/ include a sense of empathy and well-being. However, there is an increasing number of clinical reports describing patients presenting for emergency medical care after smoking /synthetic cannabinoid/ products, the most common symptoms being nausea, anxiety, agitation/panic attacks, tachycardia, paranoid ideation, and hallucinations. /Synthetic Cannabinoids/
/SIGNS AND SYMPTOMS/ Symptoms described with synthetic marijuana use are elevated heart rate, elevated blood pressure, palpitations, diaphoresis, tremulousness, anxiety, and agitation. Other physical findings may include mydriasis, although this finding is not consistent with intoxication. Psychosis with auditory and visual hallucinations is mentioned in rare circumstances, most commonly with individuals who have underlying psychiatric disorders. Seldom have seizures and arrhythmias been reported. /Synthetic Marijuana/
/SIGNS AND SYMPTOMS/ ... Accidental overdosing with a risk of severe psychiatric complications may be more likely to occur because the type and amount of cannabinoid may vary considerably from batch to batch even within the same product. In general, there may be a risk of the appearance of a full CB receptor agonist leading to life-threatening conditions if overdosed (unlike THC, which acts only as a partial agonist). /Synthetic Cannabinoids/
For more Human Toxicity Excerpts (Complete) data for Cannabicyclohexanol (6 total), please visit the HSDB record page.
/BEHAVIORAL STUDIES/ Behavioral pharmacology studies show that CP-47,497 and cannabicyclohexanol have delta9-THC-like activity in animals. In mice, it decreases overall activity, produces analgesia, decreases body temperature and produces catalepsy. Together, these four effects are used by scientists to predict delta9-THC-like psychoactivity in humans. CP-47,497's activity in all four tests suggests that it is likely to have delta9-THC-like psychoactive effects in humans.
/ALTERNATIVE and IN VITRO TESTS/ ... In the current study, /investigators/ evaluated the cytotoxicity of the synthetic cannabinoids, CP-55,940, CP-47,497 and CP-47,497-C8 towards NG 108-15 cells and investigated their mechanism of cytotoxicity. CP-55,940, CP-47,497 and CP-47,497-C8 were all cytotoxic for NG 108-15 cells in a concentration-dependent manner. The cytotoxicity of these synthetic cannabinoids was suppressed by preincubation with the selective CBv(1) receptor antagonist AM251, but not with the selective CBv(2) receptor antagonist AM630. Preincubation with a caspase-3 inhibitor significantly suppressed the cytotoxicity of these synthetic cannabinoids for NG 108-15 cells. Induction of apoptosis by these cannabinoids was also confirmed by staining of the cells with annexin V. Our results indicate that the cytotoxicity of synthetic cannabinoids towards NG 108-15 cells is mediated by the CBv(1) receptor, but not by the CBv(2) receptor, and further suggest that caspase-cascades may play an important role in the apoptosis induced by these synthetic cannabinoids.
/ALTERNATIVE and IN VITRO TESTS/ In vitro studies show that CP-47,497 and cannabicyclohexanol bind to both the brain cannabinoid receptor CB1 and the peripheral cannabinoid receptor CB2 with higher affinity than delta9-THC suggesting that it would have the same effects as THC in vivo.
Not intended for human consumption ... Identified, not quantified in related herbal products and plant food ... These substances are typically found in powder form or are dissolved in appropriate solvents, such as acetone, before being sprayed on the plant material contained in the herbal incense products. Based on law enforcement encounters, these five substances /(JWH-015, JWH-018, JWH-073, JWH-200, CP-47,497 and cannabicyclohexanol/ are typically found laced on plant material. The plant material is packaged in small pouches or packets, and is being sold over the Internet, in tobacco and smoke shops, drug paraphernalia shops, gas stations, and convenience stores as herbal incense products, giving customers of all ages direct access to these five substances.
Most psychological disturbances may be managed by simple reassurance, possibly with adjunctive use of lorazepam, diazepam, or midazolam. Sinus tachycardia usually does not require treatment but if necessary may be controlled with beta-blockers. Orthostatic hypotension responds to head down position and IV fluids. There is no specific antidote. /Marijuana/
Decontamination after ingestion. Prehospital. Administer activated charcoal if available. Hospital. Administer activated charcoal. Gastric emptying is not necessary if activated charcoal can be given promptly. Enhanced elimination. These procedures are not effective owing to the large volume of distribution of cannabinoids. /Marijuana/
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Temporary listing of substances subject to emergency scheduling. Any material, compound, mixture or preparation which contains any quantity of the following substances. 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers (DEA Code Number: 7298) are included on this list.
/Synthetic cannabinoid/ agonistic activity on the CB1 receptor is responsible for elevating mood and inducing a feeling of well-being. Some /synthetic cannabinoid/ users have reported effects similar to or even stronger than those obtained by smoking cannabis, such as physical relaxation, changes in perception, and mild euphoria.
The CP-47,497 cannabinoid compound (2-(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol) lacks the classical cannabinoid chemical structure (tricyclic benzopyran system) and is 3-28 times more potent than THC. Like its homolog cannabicyclohexanol (CP-47,497-C8), it shows higher affinity to the receptor CB1 compared to CB2, and has THC-like activity in animals. The concentration-response curve of CP-47,497-C8 in inhibiting neurotransmission in autaptic hippocampal neuron cultures is nearly identical to that described for JWH-018.
This is a Schedule I controlled substance in the USA.
No currently accepted medical use in treatment in the United States /Synthetic cannabinoids/
CP-47,497 and cannabicyclohexanol were used in basic scientific research to study structure activity relationships.
Research chemical
The popularity of these THC-like synthetic cannabinoids has significantly increased throughout the United States, and they are being abused for their psychoactive properties as reported by law enforcement, the medical community, and through scientific literature.
In the 1970s, Pfizer developed the cyclohexylphenol (CP) series. Examples include CP 59,540, CP 47,497 and their n-alkyl homologues. In the scientific literature they are referred to as 'non-classical' cannabinoids.
Two ... synthetic cannabinoids (CP-47,497 and cannabicyclohexanol) were synthesized ... for research purposes in the investigation of the cannabinoid system. ... Developed and evaluated as research tools, no other known legitimate uses have been identified for these ... synthetic cannabinoids. Furthermore, these five synthetic cannabinoids (JWH-015, JWH-018, JWH-073, JWH-200, CP-47,497 and cannabicyclohexanol) are not intended for human consumption.
Initially developed over the past 40 years as therapeutic agents, often for the treatment of pain. However, it proved difficult to separate the desired properties from unwanted psychoactive effects. /Synthetic cannabinoids/